State Street SPDR S&P Biotech ETF (XBI) Covered Calls

SPDR S&P Biotech ETF (XBI) tracks the S&P Biotechnology Select Industry Index. The fund provides equal-weighted exposure to a broad range of U.S. biotechnology companies, including those focused on drug discovery, clinical development, and advanced molecular biology. XBI is designed for investors seeking targeted exposure to the high-growth biotech sector, offering a liquid vehicle to participate in innovation and breakthroughs within the life sciences and healthcare industries.

You can sell covered calls on State Street SPDR S&P Biotech ETF to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for XBI (prices last updated Tue 11:10 AM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

The SPDR S&P Biotech ETF (XBI) is a passively managed fund that provides a comprehensive look at the biotechnology sector. Unlike broader healthcare funds that prioritize large-cap pharmaceutical giants, XBI emphasizes the innovative, often mid- and small-cap companies that are the primary drivers of R&D and new therapeutic advancements.

Core Business and Objectives

The primary objective of XBI is to replicate the performance of its underlying index. The fund employs an equal-weighting methodology, which significantly differentiates it from market-capitalization-weighted alternatives. This structure ensures that smaller, high-growth firms have as much impact on the portfolio as larger, more established companies, capturing the high-reward—and high-risk—potential of the entire biotech spectrum.

This equal-weight approach makes XBI an ideal tactical tool for investors who want broad participation in biotech innovation without being overly concentrated in a few massive firms. Because the biotech sector is driven by clinical trial results, regulatory approvals, and M&A activity, XBI’s design allows investors to gain exposure to the sector’s overall pulse, rather than betting on the success of a single drug or clinical program.

Competitive Landscape

The biotech ETF market is well-served by several highly liquid, optionable products. A primary competitor with deep options liquidity is the iShares Biotechnology ETF, which uses a market-capitalization-weighted methodology, resulting in much higher concentration in large-cap biotech companies. Another significant peer is the First Trust NYSE Arca Biotechnology Index Fund, which offers an alternative weighting scheme focused on a more concentrated list of industry players.

XBI distinguishes itself through its equal-weighting design and its massive options volume, making it the preferred instrument for traders and institutional investors seeking to hedge biotech exposure or generate premium via options strategies. Its broad diversification across the entire industry pipeline remains its key competitive advantage.

Strategic Outlook and Innovation

The fund's performance is primarily driven by the pace of medical innovation, favorable regulatory environments for drug approvals, and a robust M&A landscape. As the biotech sector continues to advance technologies like gene editing, personalized medicine, and oncology, the companies within XBI remain at the forefront of solving unmet medical needs. This constant cycle of research and discovery ensures that the fund remains dynamic over the long term.

The long-term outlook for XBI is supported by the enduring necessity of pharmaceutical innovation in the global healthcare system. For investors who seek a transparent and efficient way to participate in the biotech ecosystem, XBI provides a robust, liquid, and diverse vehicle for accessing the next generation of life-saving research and therapeutic development.

Want more examples? XAR Covered Calls | XBIT Covered Calls